The National Comprehensive Cancer Network® (NCCN®) recommends zanubrutinib (BRUKINSA®) as a preferred treatment option for people with CLL/SLL who have or haven’t been treated before and with or without certain genetic mutations, known as del(17p) or TP53 mutations*
NCCN is a not-for-profit alliance of 32 leading cancer centers in the United States devoted to patient care, research, and education. The organization creates cancer guidelines that are considered the standard to guide treatment decisions.
*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 25, 2023. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
How does BRUKINSA work?
BRUKINSA, also known as zanubrutinib, is a type of targeted treatment known as a BTK inhibitor because it works to shut down (or inhibit) a protein within cancerous B cells called Bruton’s tyrosine kinase (BTK). Shutting down the BTK protein is important because this protein sends non-stop signals to cancerous B cells, such as those that cause chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), to grow and spread.
What makes BRUKINSA different
Although some treatment options for CLL/SLL may seem similar, every treatment is different. Knowing the differences can help you take an active role in discussing treatment options with your doctor.
Blocks up to 100% of BTK
BRUKINSA was designed to block BTK signaling and keep it shut down around the clock. This may help stop the signaling in cancerous B cells.
- BRUKINSA has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The significance of blocking up to 100% of BTK on treatment responses has not been established
More effective than some other approved CLL/SLL treatments
In 2 clinical trials, BRUKINSA was shown to be much better than some other treatments approved for CLL/SLL. Two types of responses were studied: progression-free survival (PFS) and overall response rate (ORR).
- Explore BRUKINSA efficacy for patients who have not been treated, and for previously treated patients
Effective for different kinds of patients
BRUKINSA was shown to be effective, regardless of patients’ age, genetic mutations, or other health conditions such as atrial fibrillation/flutter.
- Responses were seen in patients treated with BRUKINSA, including those with genetic mutations, such as del(17p)
Low treatment discontinuation due to side effects
Fewer patients discontinued BRUKINSA due to side effects, 8% for previously untreated (compared to 14% with BR) and 15% for previously treated (compared to 22% with ibrutinib) patients.
BRUKINSA is an oral treatment that can be prescribed on a dosing schedule that meets your needs.
- BRUKINSA can be taken either once daily (4 capsules) or twice daily (2 capsules in the morning and 2 capsules later in the day). Talk to your doctor about which dosing schedule is best for you
- BRUKINSA can be taken at home, unlike many chemotherapy treatments, which have to be administered at a hospital or clinic
What is CLL/SLL?
CLL and SLL are cancers caused by abnormal B cells (also known as B lymphocytes). B cells are a type of white blood cell found in your blood and bone marrow. When B cells develop normally, they help protect the body from infection and disease.
In CLL, cancer cells are found mostly in the blood and bone marrow. In SLL, cancer cells are found mostly in the lymph nodes and spleen. The treatment for CLL and SLL is very similar because they are both caused by abnormal B cells.
For those taking BRUKINSA and their caregivers,
is here to help
is here to help
The myBeiGene patient support program provides a dedicated Oncology Nurse Advocate who is available to answer questions and provide information about your cancer, treatment with BRUKINSA, follow-up support, and more.
Call 1-833-BEIGENE (1-833-234-4363) Monday through Friday, 8 AM to 8 PM Eastern Time to speak with an Oncology Nurse Advocate today.
myBeiGene® is not insurance and does not guarantee product coverage or reimbursement.